How biotech Alnylam plans to make a profit, and what stands in its way

Despite having revenue from two commercial products, Alnylam Pharmaceuticals lost $886 million in 2019 — its biggest-ever net loss. But CEO John Maraganore believes the biotech could soon be one of the top five biopharma companies in the country.